Summary by Moomoo AI
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share for the quarter ended July 31, 2024. However, the company has disclosed its stock-based compensation expenses, which decreased year-on-year from $124,646 in 2023 to $54,554 in 2024. The company also reported a cumulative net operating loss for federal income tax purposes of approximately $56 million as of July 31, 2024, an increase from $54 million at the end of the previous fiscal year. Heart Test Laboratories has a long-term operating lease for its facilities, with rent expense for the quarter amounting to approximately $37,000. In terms of business development, the company has entered into collaboration agreements with Rutgers and Mount Sinai...Show More